Paperpal Prime Logo

Signal Transduction and Targeted Therapy : Impact Factor & More

eISSN: 2059-3635pISSN: 2095-9907
JournalOpen Access

Key Metrics

CiteScore
18.4
Impact Factor
>= 25
Scite Index
0.93 5-Year SI
SJR
Q1Genetics
SNIP
3.98
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Signal Transduction and Targeted Therapy

Signal Transduction and Targeted Therapy Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher SPRINGERNATURE
Language English
Frequency Continuous publication
Article Processing ChargesEUR 2690 | USD 3190 | GBP 2390
Publication Time5
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
Society/Institute/SponsorSichuan University
FrequencyContinuous publication
Publication Start Year2016
Publisher URLVisit website
Website URLVisit website
Publication Details
Other chargesVisit website
PlagiarismVisit website
Publication Time 5
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
License typeCC BY
OA statementVisit website
View less

Planning to publish in Signal Transduction and Targeted Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Signal Transduction and Targeted Therapy

Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in cancer
  • 7 Aug 2026
  • Signal Transduction and Targeted Therapy
Calr-mediated calcium buffering: a molecular barrier to in vivo cardiac reprogramming
  • 7 Aug 2026
  • Signal Transduction and Targeted Therapy
Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study
  • 6 Aug 2026
  • Signal Transduction and Targeted Therapy
RNA methyltransferase 3 drives pancreatic acinar cell carcinoma growth and is a therapeutic target
  • 6 Aug 2026
  • Signal Transduction and Targeted Therapy
RAF1 extrachromosomal DNA amplification confers acquired erlotinib resistance in a non-small cell lung cancer cell model
  • 5 Aug 2026
  • Signal Transduction and Targeted Therapy
Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets
  • 5 Aug 2026
  • Signal Transduction and Targeted Therapy
Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in cancer
  • 7 Aug 2026
  • Signal Transduction and Targeted Therapy
Calr-mediated calcium buffering: a molecular barrier to in vivo cardiac reprogramming
  • 7 Aug 2026
  • Signal Transduction and Targeted Therapy
Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study
  • 6 Aug 2026
  • Signal Transduction and Targeted Therapy
RNA methyltransferase 3 drives pancreatic acinar cell carcinoma growth and is a therapeutic target
  • 6 Aug 2026
  • Signal Transduction and Targeted Therapy
RAF1 extrachromosomal DNA amplification confers acquired erlotinib resistance in a non-small cell lung cancer cell model
  • 5 Aug 2026
  • Signal Transduction and Targeted Therapy
Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets
  • 5 Aug 2026
  • Signal Transduction and Targeted Therapy

FAQs on Signal Transduction and Targeted Therapy